The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS.
Qiongman
Q
Kong
Sarah
S
Carothers
Yueming
Y
Chang
Chien-Liang
CL
Glenn Lin
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage; D002443:Ceftriaxone / Q000008:administration & dosage*; D004195:Disease Models, Animal; D018450:Disease Progression; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004359:Drug Therapy, Combination; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D008911:Minocycline / Q000008:administration & dosage*; D012107:Research Design; D013482:Superoxide Dismutase; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage; D000099156:Superoxide Dismutase 2
D000900:Anti-Bacterial Agents; D000975:Antioxidants; D002443:Ceftriaxone; D008911:Minocycline; D013482:Superoxide Dismutase; D014810:Vitamin E; D000099156:Superoxide Dismutase 2